Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas

Tina A. Ayeni, Jamie N Bakkum-Gamez, Andrea Mariani, Michaela E. McGree, Amy L. Weaver, Michael Haddock, Gary Keeney, Harry J. Long, Sean Christopher Dowdy, Karl C. Podratz

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objective The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Methods Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. Results From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P =.10) or in stage-for-stage comparative analyses (stage I/II, P =.45; stage III, P =.46; stage IV, P =.65). The 5-year cause-specific survival in stage I/II was 84.8%, 89.8%, and 83.9% for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P =.02). For stage III, 5-year OS was 49.2% and 40.0% for G3EC and USC, respectively; multivariable modeling identified age (P <.001), LVSI (P <.001), unresectable nodal disease (P =.03), and regional radiotherapy (P =.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7% and 12.1% for G3EC and USC, respectively; multivariable modeling identified LVSI (P =.002), cervical stromal invasion (P =.02), and adjuvant chemotherapy (P =.02) but not residual disease as independent prognostic factors. Conclusions When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.

Original languageEnglish (US)
Pages (from-to)478-485
Number of pages8
JournalGynecologic Oncology
Volume129
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Outcome Assessment (Health Care)
Carcinoma
Survival
Therapeutics
Adjuvant Chemotherapy
Radiotherapy

Keywords

  • Clinicopathologic prognostic factors
  • High-risk uterine carcinomas
  • Outcomes assessment

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. / Ayeni, Tina A.; Bakkum-Gamez, Jamie N; Mariani, Andrea; McGree, Michaela E.; Weaver, Amy L.; Haddock, Michael; Keeney, Gary; Long, Harry J.; Dowdy, Sean Christopher; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 129, No. 3, 06.2013, p. 478-485.

Research output: Contribution to journalArticle

Ayeni, Tina A. ; Bakkum-Gamez, Jamie N ; Mariani, Andrea ; McGree, Michaela E. ; Weaver, Amy L. ; Haddock, Michael ; Keeney, Gary ; Long, Harry J. ; Dowdy, Sean Christopher ; Podratz, Karl C. / Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. In: Gynecologic Oncology. 2013 ; Vol. 129, No. 3. pp. 478-485.
@article{afc182df66e94ff99d0780880edb36eb,
title = "Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas",
abstract = "Objective The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Methods Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. Results From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P =.10) or in stage-for-stage comparative analyses (stage I/II, P =.45; stage III, P =.46; stage IV, P =.65). The 5-year cause-specific survival in stage I/II was 84.8{\%}, 89.8{\%}, and 83.9{\%} for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P =.02). For stage III, 5-year OS was 49.2{\%} and 40.0{\%} for G3EC and USC, respectively; multivariable modeling identified age (P <.001), LVSI (P <.001), unresectable nodal disease (P =.03), and regional radiotherapy (P =.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7{\%} and 12.1{\%} for G3EC and USC, respectively; multivariable modeling identified LVSI (P =.002), cervical stromal invasion (P =.02), and adjuvant chemotherapy (P =.02) but not residual disease as independent prognostic factors. Conclusions When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.",
keywords = "Clinicopathologic prognostic factors, High-risk uterine carcinomas, Outcomes assessment",
author = "Ayeni, {Tina A.} and Bakkum-Gamez, {Jamie N} and Andrea Mariani and McGree, {Michaela E.} and Weaver, {Amy L.} and Michael Haddock and Gary Keeney and Long, {Harry J.} and Dowdy, {Sean Christopher} and Podratz, {Karl C.}",
year = "2013",
month = "6",
doi = "10.1016/j.ygyno.2013.03.011",
language = "English (US)",
volume = "129",
pages = "478--485",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas

AU - Ayeni, Tina A.

AU - Bakkum-Gamez, Jamie N

AU - Mariani, Andrea

AU - McGree, Michaela E.

AU - Weaver, Amy L.

AU - Haddock, Michael

AU - Keeney, Gary

AU - Long, Harry J.

AU - Dowdy, Sean Christopher

AU - Podratz, Karl C.

PY - 2013/6

Y1 - 2013/6

N2 - Objective The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Methods Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. Results From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P =.10) or in stage-for-stage comparative analyses (stage I/II, P =.45; stage III, P =.46; stage IV, P =.65). The 5-year cause-specific survival in stage I/II was 84.8%, 89.8%, and 83.9% for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P =.02). For stage III, 5-year OS was 49.2% and 40.0% for G3EC and USC, respectively; multivariable modeling identified age (P <.001), LVSI (P <.001), unresectable nodal disease (P =.03), and regional radiotherapy (P =.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7% and 12.1% for G3EC and USC, respectively; multivariable modeling identified LVSI (P =.002), cervical stromal invasion (P =.02), and adjuvant chemotherapy (P =.02) but not residual disease as independent prognostic factors. Conclusions When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.

AB - Objective The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Methods Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. Results From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P =.10) or in stage-for-stage comparative analyses (stage I/II, P =.45; stage III, P =.46; stage IV, P =.65). The 5-year cause-specific survival in stage I/II was 84.8%, 89.8%, and 83.9% for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P =.02). For stage III, 5-year OS was 49.2% and 40.0% for G3EC and USC, respectively; multivariable modeling identified age (P <.001), LVSI (P <.001), unresectable nodal disease (P =.03), and regional radiotherapy (P =.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7% and 12.1% for G3EC and USC, respectively; multivariable modeling identified LVSI (P =.002), cervical stromal invasion (P =.02), and adjuvant chemotherapy (P =.02) but not residual disease as independent prognostic factors. Conclusions When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.

KW - Clinicopathologic prognostic factors

KW - High-risk uterine carcinomas

KW - Outcomes assessment

UR - http://www.scopus.com/inward/record.url?scp=84877584557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877584557&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.03.011

DO - 10.1016/j.ygyno.2013.03.011

M3 - Article

VL - 129

SP - 478

EP - 485

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -